HCM
VRTX icon

Herndon Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Herndon Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-23
Closed -$2K – 540
2016
Q3 		$2K Hold
23
– – ﹤0.01% 397
2016
Q2 		$2K Buy
+23
New +$1.99K ﹤0.01% 412

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Herndon Capital Management's VRTX Position: Q4 2016 in Review

Herndon Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2016, closing a stake of 23 shares — an estimated $2K sold.

Herndon Capital Management first reported a position in VRTX in Q2 2016 and held it in 2 quarters. The position peaked at $2K in Q3 2016. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

  • Herndon Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Herndon Capital Management sold 23 Vertex Pharmaceuticals shares in Q4 2016, an estimated $2K.
  • Herndon Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Herndon Capital Management's Vertex Pharmaceuticals position peaked at $2K in Q3 2016.
  • 483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on Herndon Capital Management's 13F filing for Q4 2016, filed 2 Feb 2017.